When Should You Start Hormone Replacement Therapy?

For most women, the window of most favorable benefit-to-risk balance for starting hormone replacement therapy (HRT) is within 10 years of the final menstrual period and before age 60 (The 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Starting outside that window doesn't automatically rule treatment out. But it does call for a more individualized risk discussion with a licensed provider.

There is no single "right day" to start. The decision depends on your symptoms, health history, and personal goals, made together with a physician.

What This Means

If you're having hot flashes, night sweats, sleep disruption, or vaginal dryness tied to perimenopause or menopause, timing matters almost as much as the decision to treat at all.

Research consistently shows that women who begin HRT close to the onset of menopause tend to see a more favorable balance of benefits and risks than women who start a decade or more after their final period (Hodis & Mack, 2022).

That doesn't mean older women are automatically excluded from treatment. It means the conversation with your provider becomes more nuanced, weighing your personal cardiovascular, breast, and bone-health history more heavily.

Candidacy

Reasonable candidates for HRT are generally women with bothersome vasomotor symptoms (hot flashes, night sweats), sleep disturbance, or genitourinary symptoms of menopause who are within about 10 years of their final period or under age 60, and who have no contraindications (Stuenkel et al., 2015).

Contraindications and cautions include:

• A personal history of breast cancer.
• Unexplained vaginal bleeding.
• Active blood clots or a history of venous thromboembolism.
• Certain liver disease.
• A history of stroke or heart attack.

Women who are more than 10 years past menopause, older than 60, or who carry higher baseline cardiovascular risk are not automatically excluded. But they typically need a more careful, individualized evaluation before starting (The 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Clinical Evaluation

A thorough evaluation before starting HRT typically includes a detailed personal and family medical history (breast cancer, blood clots, cardiovascular disease, liver disease), a physical exam, blood pressure check, and a review of when your last menstrual period occurred.

Many clinicians also review mammogram status, bone density risk factors, and, depending on symptoms, baseline labs such as lipid panels or thyroid function to rule out other causes of symptoms.

Hormone levels themselves, like FSH or estradiol, are not always required to diagnose menopause. They are generally more useful in younger women with atypical symptoms than as a routine screening step.

The goal of this evaluation is to confirm that your symptoms are consistent with the menopause transition, and that no contraindication changes the benefit-risk calculation.

Available Options

HRT is not a single product. Options include:

• Systemic estrogen-alone therapy (for women without a uterus).
• Combined estrogen-progestogen therapy (for women with a uterus, to protect the uterine lining).
• Low-dose vaginal estrogen for genitourinary symptoms alone, which carries a different risk profile than systemic therapy (U.S. Food and Drug Administration, 2026).

Delivery methods include pills, transdermal patches, gels, sprays, and vaginal rings or creams. The Endocrine Society specifically notes transdermal estrogen may be preferable for women with elevated clotting risk (Stuenkel et al., 2015).

Conventional non-hormonal alternatives also exist and are appropriate first-line options for some women. These include certain SSRIs/SNRIs, gabapentin, oxybutynin, and newer non-hormonal medications approved specifically for hot flashes, as well as lifestyle strategies like layered clothing, cooling techniques, and cognitive behavioral therapy for insomnia.

A licensed provider can walk through which category fits your symptoms, uterine status, and risk profile.

Benefits, Limitations & Risks

Benefits

The real benefit of well-timed HRT is meaningful symptom relief.

HRT remains the most effective treatment available for hot flashes and night sweats, along with prevention of bone loss and, per recent FDA-reviewed data, a reduction in all-cause mortality and fracture risk when started within 10 years of menopause onset (U.S. Food and Drug Administration, 2026).

Limitations and risks

It is not a guaranteed fix for every menopause-related complaint, and it does not prevent aging itself. Real risks and limitations remain relevant even after 2026 label updates. Risk varies by individual health history, hormone type, dose, and route of administration.

Factors like personal or family history of breast cancer, clotting disorders, and cardiovascular disease change the calculation for any individual patient (The 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Results and side-effect profiles vary from person to person, and ongoing monitoring is required. This is a prescription decision, not a one-time purchase.

What the Evidence Shows

What's established

Current evidence, including large randomized trials and long-term follow-up data, supports that starting HRT close to menopause onset is associated with reduced all-cause mortality, fewer fractures, and a more favorable cardiovascular risk profile than starting later (Hodis & Mack, 2022).

In February 2026, the FDA approved the removal of boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from six menopausal hormone therapy products, citing a comprehensive review of the scientific literature (U.S. Food and Drug Administration, 2026).

What evidence does not establish

The evidence does not establish that HRT is risk-free for every woman regardless of age or health history, or that starting HRT more than 10 years after menopause carries the same favorable profile as starting earlier.

The timing relationship is well-supported, but it is not a guarantee for any individual patient (Hodis & Mack, 2022).

Ongoing research continues to refine which formulations, doses, and delivery routes carry the most favorable risk profiles for specific patient groups.

Recovery / Next Steps

There's no "recovery" period in the surgical sense, but there is an adjustment period.

Most women notice symptom changes within a few weeks of starting therapy, though it can take up to two to three months to assess the full effect of a given dose and formulation.

Expect a follow-up visit within the first few months to reassess symptoms, tolerability, and, if applicable, any bleeding pattern changes.

Periodic reevaluation continues for as long as therapy continues (The 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Dose and delivery method are often adjusted more than once before landing on the right fit.

Orlando Considerations

Florida's heat and humidity can intensify vasomotor symptoms like hot flashes and night sweats for many women. That's one reason local patients often raise the topic of timing sooner rather than later.

Hormone therapy in Florida must be prescribed and monitored by a licensed physician or advanced practice provider under Florida's medical practice laws. It is not available over the counter or through unsupervised compounding.

If you're establishing care with a new provider in the Orlando area, bring your medical history and any recent labs or mammogram results to your first visit to help streamline the evaluation described above.

Frequently Asked Questions

Is there a hard cutoff age after which I can't start HRT?

No single cutoff applies to everyone. Risk generally rises for women starting more than 10 years after menopause or after age 60. But candidacy is individualized based on your health history, not age alone (The 2022 Hormone Therapy Position Statement Advisory Panel, 2022).

Can I start HRT during perimenopause, before my periods stop completely?

Yes — many women start therapy during perimenopause for symptom control. Your provider will factor in whether you still need contraception and whether cyclic or continuous dosing makes more sense for you.

Do I need blood tests to know if I'm ready to start?

Not always. Menopause is usually diagnosed based on age and menstrual history rather than hormone levels. But labs may be used to rule out other causes of your symptoms, or to guide dosing in specific situations.

What happens if I wait too long to start?

Waiting doesn't eliminate your options, but the benefit-risk balance may shift, and your provider may recommend additional cardiovascular or breast-health screening before starting, or suggest a non-hormonal option instead.

Is bioidentical hormone therapy different from standard HRT in terms of timing guidance?

The same timing principles apply. "Bioidentical" describes the hormone's molecular structure, not a different safety profile — FDA-approved bioidentical products are held to the same evaluation and monitoring standards as other regulated hormone therapies.

References

Hodis, H. N., & Mack, W. J. (2022). Menopausal hormone replacement therapy and reduction of all-cause mortality and cardiovascular disease: It's about time and timing. Cancer Journal, 28(3), 208-223. https://pmc.ncbi.nlm.nih.gov/articles/PMC9178928/

Mayo Clinic. (n.d.). Hormone therapy: Is it right for you? https://www.mayoclinic.org/diseases-conditions/menopause/in-depth/hormone-therapy/art-20046372

Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015). Treatment of symptoms of the menopause: An Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. https://doi.org/10.1210/jc.2015-2236

The 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028

U.S. Food and Drug Administration. (2026, February 12). FDA approves labeling changes to menopausal hormone therapy products. https://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products

This article is for educational purposes only and is not a substitute for individualized medical advice.

Hormone replacement therapy is a prescription treatment that requires evaluation, lab work as indicated, and ongoing monitoring by a licensed physician or provider — please consult a qualified healthcare professional before starting or stopping any hormone therapy.

Medically reviewed by Kenny Chantasi, DO. Last medically reviewed: August 6, 2026.

Related reading

• How Hormone Therapy Works: Pellets vs. Injection Hormones
• Low Testosterone Treatment Options Explained
• Who Is a Good Candidate for Hormone Replacement Therapy?

More questions answered on the PrimeCell patient blog, or see frequently asked questions.

Related services at PrimeCell

PrimeCell is a physician-led practice in Orlando. Candidacy for any procedure is determined at an in-person evaluation.